Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1411-1420 of 10980

Edit search filters
  1. Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

    Rochester, MN

  2. The Ventilatory Response to Activation of the Locomotor Afferents in Normoxic and Hypoxic Conditions

    Rochester, MN

  3. A Study of PDD in Type 2 Diabetes

    Rochester, MN

  4. A Study of XmAb ®18087 in Subjects With NET and GIST

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Multi-center ESG Randomized Interventional Trial (MERIT-Trial)

    Rochester, MN

  6. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

    Rochester, MN

  7. COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

    Rochester, MN

  8. An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  9. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer

    Rochester, MN

  10. A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET

    Rochester, MN

.

Mayo Clinic Footer